Summary of the Shareholders' Meeting of Guilin Sanjin Pharmaceutical Co., Ltd. Core Viewpoint The shareholders' meeting of Guilin Sanjin Pharmaceutical Co., Ltd. was conducted in compliance with relevant laws and regulations, with all proposed resolutions being approved by the shareholders present. Group 1: Meeting Procedures - The shareholders' meeting was convened by the company's eighth board of directors and announced in advance, detailing the time, location, voting methods, and agenda [1][2][3] - The meeting utilized a combination of on-site voting and online voting, held on May 16, 2025, at the company's conference room in Guilin [2][3] - The legal compliance of the meeting's procedures was verified by the appointed lawyers, confirming adherence to the Company Law and the company's articles of association [4][5] Group 2: Attendance and Voting - A total of 82 shareholders and representatives attended the meeting, representing 417,031,460 shares, which is 70.9758% of the total voting shares [3][4] - Among the attendees, 15 were present at the venue, representing 412,512,257 shares (70.2067%), while 67 participated via online voting, representing 4,519,203 shares (0.7691%) [3] - The attendance included 76 minority shareholders, representing 14,315,780 shares (2.4364%) [3] Group 3: Voting Results - All proposed resolutions were passed with overwhelming support, including the annual report, board and supervisory committee reports, financial statements, and profit distribution plans [6][7][8][9][10] - For the first resolution regarding the 2024 annual report, 417,013,260 shares (99.9956%) voted in favor, with only 5,200 shares (0.0031%) against [6] - The resolutions concerning the remuneration of directors and senior management were also approved, with votes consistently exceeding 99% in favor [11][12][13][14][15] Group 4: Legal Opinion - The lawyers concluded that the meeting's convening, attendance, voting procedures, and results were all legally valid and in accordance with the relevant laws and regulations [23][24]

一、 本次股东大会的召集与召开程序 本次股东大会由公司第八届董事会第十三次会议决议召集。公司于 2025 年 4 月 26 日在《中国证券报》《证券时报》《证券日报》及巨潮资讯网 （www.cninfo.com.cn）上公告了《关于召开 2024 年度股东大会的通知》（以下 简称"会议通知"），会议通知载明了本次股东大会的召开时间和地点、投票方 式、会议召开方式、股权登记日、出席人员、会议审议事项和提案、会议登记相 关事项等内容。 本次股东大会采取现场表决和网络投票相结合的表决方式。本次股东大会现 场会议于 2025 年 5 月 16 日 14:30 在广西桂林市临桂区人民南路 9 号公司四楼会 议室如期举行。网络投票时间为：（1）通过深圳证券交易所交易系统进行网络 投票的具体时间为：2025 年 5 月 16 日 9:15-9:25，9:30-11:30 和 13:00-15:00；（2） 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间 为：2025 年 5 月 16 日 9:15-15:00 期间的任意时间。 关于桂林三金药业股份有限公司 2024 年 ...

Inventory Management - The company has upgraded its inventory management system, utilizing a BI intelligent analysis system and a professional data analysis team to balance market demand dynamics and cost control [1] - The overall inventory level has significantly decreased compared to the same period last year, maintaining a healthy inventory cycle of 1.5 to 2 months [1] Product Growth Potential - The growth trend for the company's second and third-line products is positive, with specific products like the Hejia Danchuan capsule expected to maintain last year's growth rate [1] - The Xuanyunning series has surpassed 100 million in sales in 2021, aiming for double-digit growth this year [1] - Other products, such as Shuyanquing spray and Fufang Ganmaoling granules, are also expected to maintain high growth rates [1] Dividend Policy - The company has consistently implemented a cash dividend policy, proposing a cash dividend of 3.5 yuan per 10 shares for 2024, totaling 206 million yuan [2] - The dividend policy is expected to remain stable unless there are special funding needs [2] Biopharmaceutical Development - Biopharmaceuticals are a key part of the company's dual strategy, facing high investment and risk, with the industry currently experiencing a downturn [2] - The company is optimizing its R&D pipeline, focusing on projects with promising clinical data, such as the BC006 monoclonal antibody injection, which is nearing the completion of Phase I clinical trials [2] - Efforts are being made to control costs and expenses while seeking partnerships in the biopharmaceutical sector [2]

证券代码：002275 证券简称：桂林三金 编号：2025-020 桂林三金药业股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示 1.本次股东大会未出现否决提案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1.召开时间： （1）现场会议召开时间：2025年5月16日14:30； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为2025年5 月16日9:15—9:25,9:30—11:30 和13:00—15:00；通过深圳证券交易所互联网 投票系统（http://wltp.cninfo.com.cn）投票时间为2025年5月16日9:15-15:00 期间的任意时间。 2.现场会议召开地点：广西壮族自治区桂林市临桂区人民南路9号公司四楼 会议室 3.召开方式：现场投票与网络投票相结合的方式 4.召集人：公司董事会 5.主持人：董事长邹洵先生 6.公司已于2025年4月26日在《中国证券报》《证券时报》《证券日报》及 巨潮资讯网发布了《关于召开2024年度股东大会的 ...

证券代码：002275 证券简称：桂林三金 公告编号：2025-019 桂林三金药业股份有限公司 关于召开2024年度业绩说明会并征集问题的公告 2.召开方式：网络远程文字交流的方式。 3. 参 与 方 式 ： 投 资 者 可 登 录 深 圳 证 券 交 易 所 " 互 动 易 " 平 台 （http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次年度业绩说明会。 4.公司出席人员：董事长、总裁邹洵先生，董事、副总裁兼财务负责人谢元 钢先生，副总裁兼董事会秘书李春先生，独立董事陈亮先生。 二、投资者问题征集事宜 为充分尊重投资者、提升交流的针对性，现就公司2024年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可在本次业绩说 明会召开前登录深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn） 进入"业绩说明会提问预征集"专题页面或扫描下方二维码提交问题，公司将在 2024年度业绩说明会上对投资者普遍关注的问题进行回答。业绩说明会召开交流 期间，投资者仍可登录活动界面进行互动提问。 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 ...

Core Viewpoint - The company has shown growth in revenue and profit for the fiscal year 2024, but faces challenges in its biopharmaceutical segment due to a competitive environment and high R&D costs [2][3]. Financial Performance - In 2024, the company achieved total revenue of 2.19 billion yuan, a 1.03% increase from 2.17 billion yuan in the previous year [2]. - Profit before tax reached 643.94 million yuan, up 24.24% from 518.28 million yuan year-on-year [2]. - Net profit attributable to shareholders was 521.53 million yuan, reflecting a 23.79% increase from 421.30 million yuan [2]. - In Q1 2025, the company reported a net profit of 97.67 million yuan, an 11.61% increase from 87.52 million yuan in the same period last year [2]. Biopharmaceutical Segment - The biopharmaceutical sector is a key part of the company's strategy but is currently facing a cooling market with high competition and investment risks [2][3]. - The company is optimizing its R&D pipeline, focusing on projects with promising clinical data, such as the BC006 monoclonal antibody injection, which is nearing completion of Phase I clinical trials [3]. Inventory and Sales Management - The company has improved its inventory management through a BI intelligent analysis system, achieving a healthier inventory cycle of 1.5 to 2 months [5]. - The company has implemented diverse promotional activities to stimulate end-market consumption and optimize inventory structure [5]. Product Development - The company is optimistic about the growth potential of its second and third-tier products, with specific products like the Guaifenesin capsule and the dizziness relief series expected to maintain or achieve significant growth [6]. Dividend Policy - The company has a consistent cash dividend policy, proposing a cash dividend of 0.35 yuan per share for 2024, totaling 206 million yuan [8]. - The company aims to maintain stable operating cash flow to support its dividend policy unless special funding needs arise [7]. Sales Expense Management - The company has been strict in controlling sales expenses, focusing on second and third-tier products while maintaining a balanced sales expense ratio [9].

Financial Performance - In 2024, the company achieved total revenue of 2,193.99 million CNY, a growth of 1.03% compared to 2023's 2,171.60 million CNY [1] - The total profit reached 643.94 million CNY, an increase of 24.24% from 518.28 million CNY in the previous year [1] - Net profit attributable to shareholders was 521.53 million CNY, up 23.79% from 421.30 million CNY year-on-year [1] - In Q1 2025, the net profit after deducting non-recurring gains and losses was 97.67 million CNY, reflecting an 11.61% increase from 87.52 million CNY in Q1 2024 [1] Business Development - The biopharmaceutical sector is a key part of the company's dual-wing strategy, facing high investment and long R&D cycles, with current market conditions being challenging [1] - The company is experiencing increased competition and a diverse customer base, leading to some idle capacity in the CDMO supply chain [1] - Ongoing projects in the biopharmaceutical pipeline are still in the R&D phase, with limited revenue from technical services [1] - The company is optimizing costs and personnel structure while focusing on promising projects, such as the BC006 monoclonal antibody injection, which is nearing completion of Phase I clinical trials [1] Inventory and Sales Management - The company has upgraded its inventory management system, utilizing BI analytics to enhance market demand alignment and cost control [2] - The overall inventory level has improved significantly, maintaining a healthy cycle of 1.5 to 2 months, which supports operational quality and cost optimization [2] - The company has implemented diverse promotional activities to stimulate market demand and optimize inventory across channels [2] Product Growth and Dividends - The growth trend for second and third-tier products remains positive, with specific products like the Guaifenesin capsule expected to continue strong growth [2] - The company plans to maintain its cash dividend policy, proposing a distribution of 3.5 CNY per 10 shares, totaling 206 million CNY for 2024 [2] Sales Expense Management - The company has adopted a more precise approach to sales expense allocation, focusing on second and third-tier products while maintaining a low expense ratio for first-tier products [3] - Overall sales expenses are aligned with sales revenue, indicating no significant changes in the sales expense ratio for the year [3]

Group 1 - Kexin Technology plans to repurchase shares worth between 30 million and 50 million yuan, with a maximum repurchase price of 80 yuan per share, for employee stock ownership plans or capital reduction [1] - Jiahua Technology's shareholder plans to reduce holdings by up to 1.5% of the company's total shares, amounting to a maximum of 116,000 shares, between May 28, 2025, and August 25, 2025 [1] - Beiqi Blue Valley's subsidiary reported cumulative sales of 38,041 vehicles this year, representing a year-on-year increase of 192.53% [2] Group 2 - AVIC Finance plans to transfer shares of AVIC Xi'an Aircraft Industry Group and AVIC Onboard Systems, totaling 4.067 billion yuan, to its controlling shareholder [2] - Haide shares' executives plan to increase their holdings by at least 20.73 million yuan within six months [3] - Dabeinong's subsidiary received planting approval for genetically modified soybeans in Brazil, marking significant progress in the South American market [4] Group 3 - Yongan Pharmaceutical's chairman is under investigation, but the company's operations remain normal [4] - Teruid's subsidiary is expected to win a 126 million yuan project from the State Grid, which will enhance the company's brand and industry influence [4][5] - Junxin shares plan to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 30.57 yuan per share [5] Group 4 - Meinian Health plans to reduce its holdings by up to 3% of the company's total shares, amounting to a maximum of 11.7 million shares, starting from May 27, 2025 [7] - Electric Power Investment is planning a major asset restructuring, leading to a temporary suspension of its stock [9] - Tongda shares are expected to win a 207 million yuan project from the State Grid, which will positively impact future operating performance [10] Group 5 - Xintian Technology's major shareholder plans to reduce holdings by up to 3% of the company's total shares, amounting to a maximum of 580,410 shares [11] - Huizhou Intelligent's controlling shareholder and some executives plan to increase their holdings by between 29.2 million and 58.4 million yuan [12] - Zhongdali De plans to sell a 50% stake in Shanghai Ketaike Transmission System Co., Ltd. for 9.2777 million yuan to optimize its asset structure [14] Group 6 - Jinlitai's stock will be suspended due to the inability to disclose periodic reports within the statutory deadline [15] - Chuhuan Technology's major shareholder plans to reduce holdings by up to 3% of the company's total shares, amounting to a maximum of 239,560 shares [15] - Guilin Sanjin's subsidiary received approval for clinical trials of a new indication for a monoclonal antibody injection [16] Group 7 - Plit plans to sign a strategic supply agreement for sodium-ion batteries, committing to supply at least 1 GWh over four years [17] - Dalian Electric Porcelain's subsidiary is expected to win a project worth approximately 71 million yuan from the State Grid [18]

证券代码：002275 证券简称：桂林三金 公告编号：2025-018 桂林三金药业股份有限公司 关于控股孙公司 BC006 单抗注射液新增适应症获得药 物临床试验批准的公告 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 2 月 17 日受理的 BC006 单抗注射液临床试验申请符合药品注册的有关要求， 同意本品开展用于特发性肺纤维化适应症的临床试验。 二、该药品研发及相关情况 公司已于 2021 年 3 月收到国家药品监督管理局核准签发的 BC006 单抗注射 液的临床试验批件，拟用于治疗晚期恶性肿瘤，有望解决在多种实体瘤、血液肿 瘤、骨关节疾病等疾病领域未能满足的医疗需求。详细内容见公司于 2021 年 3 月 22 日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于控股孙公司 获得药物临床试验批准的公告》（公告编号：2021-002）。该适应症临床试验目前 处于 I 期临床试验进行中。 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 近日，桂林三金药业股份有限公司（以下简称"公司"）控 ...

Group 1: Financial Performance - In 2024, the company achieved total revenue of 2,193.99 million yuan, a 1.03% increase from 2,171.60 million yuan in the previous year [1] - The total profit reached 643.94 million yuan, up 24.24% from 518.28 million yuan year-on-year [1] - The net profit attributable to shareholders was 521.53 million yuan, reflecting a 23.79% growth compared to 421.30 million yuan in the previous year [1] - In Q1 2025, the net profit excluding non-recurring gains and losses was 97.67 million yuan, an 11.61% increase from 87.52 million yuan in the same period last year [1] Group 2: Inventory Management - The company has upgraded its inventory management system, utilizing a BI intelligent analysis system to enhance efficiency [1] - The inventory turnover period is maintained at a healthy level of 1.5 to 2 months, indicating effective inventory control [1] - Overall inventory levels have significantly decreased compared to previous years, supporting operational quality and cost optimization [1] Group 3: Product Development and Market Trends - The company expects good growth trends for its second and third-line products, with specific products like Hakeke Dinhua Capsules anticipated to maintain last year's growth rate [2] - The sales of the Xuanyun Ning series surpassed 100 million yuan in 2021, with a target of achieving double-digit growth this year [2] - The company is focusing on optimizing its R&D pipeline, particularly for promising projects like the BC006 monoclonal antibody injection, which is nearing the completion of Phase I clinical trials [2] Group 4: Sales and Marketing Strategy - The company is adopting a more precise approach to sales expenses, with a focus on second and third-line products [2] - Sales expenses are expected to align with sales revenue, maintaining a stable sales expense ratio throughout the year [2] - The promotion of Sanjin Granules in hospitals is progressing well, although its overall contribution to sales remains limited due to a small base [3] Group 5: Dividend Policy - The company has a consistent cash dividend policy, proposing a distribution of 3.5 yuan per 10 shares, totaling 206 million yuan for 2024 [3] - The dividend policy is subject to the company's operational needs and sustainable development capabilities [3]